The multikinase inhibitor midostaurin has also demonstrated potent in vitro activity against KIT D816V (Gleixner et al. 2006; Weisberg et al. 2002; Fabbro et al. 2000) as well as activity in patients with advanced SM with this mutation (Gotlib et al. 2010). Here, KIT is linked to systemic mastocytosis.